Table 1 Main characteristics of including studies
Reference | Year | Place | Type | Number of patients | Follow-up | Age Mean ± SD/median (range) | Sex (male/female) | ASA | TNM stage* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FT | TC | FT | TC | |||||||||||||||
FT | TC | FT | TC | FT | TC | I/II | III/IV | I/II | III/IV | ≤stage II | >stage II | ≤stage II | >stage II | |||||
Lee [19] | 2011 | Korea | RCT | 46 | 54 | 1 month | 61.9 ± 11.2 | 60.6 ± 10.0 | 26/20 | 30/24 | 43 | 2 | 51 | 3 | 23 | 21 | 31 | 21 |
Vlug [18] | 2011 | Netherlands | RCT | 100 | 109 | 30 days | 66 ± 8.6 | 68 ± 8.8 | 53/47 | 68/41 | 82 | 21 | 87 | 22 | NA | NA | NA | NA |
Q.Wang [16] | 2012 | China | RCT | 40 | 38 | More than one month | 71(65-81) | 72(65-82) | 22/18 | 20/18 | NA | NA | NA | NA | 18 | 22 | 18 | 20 |
G.Wang [17] | 2012 | China | RCT | 40 | 40 | 30 days | 55.7 ± 17.3 | 56.1 ± 14.6 | 27/13 | 26/14 | 33 | 7 | 36 | 4 | 24 | 16 | 27 | 13 |
Feng [20] | 2014 | China | RCT | 57 | 59 | 4 weeks | 54.0 ± 12.0 | 56.3 ± 11.5 | 36/21 | 40/19 | 57 | 0 | 59 | 0 | 35 | 22 | 30 | 29 |
Esteban [23] | 2014 | Spain | CCT | 150 | 56 | 30 days | 68.04 ± 9.9 | 64.8 ± 14 | 70/80 | 28/28 | 99 | 49 | 44 | 11 | NA | NA | NA | NA |
Gouvas [21] | 2012 | Greece | CCT | 42 | 33 | 1Â month | 64(31-83) | 68(34-85) | 22/20 | 11/22 | 37 | 5 | 29 | 4 | 35 | 7 | 28 | 5 |
Poon [22] | 2010 | Chinese HongKong | CCT | 96 | 84 | Till discharge | 72(31-94) | 72(46-92) | 51/45 | 50/34 | 83 | 13 | 68 | 16 | 54 | 42 | 43 | 41 |
Vassiliki [24] | 2009 | USA | CCT | 82 | 115 | Till discharge | 68.2 ± 13.4 | 69.3 ± 11.9 | 36/46 | 60/55 | 56 | 26 | 76 | 39 | NA | NA | NA | NA |
Huibers [25] | 2012 | Netherlands | CCT | 43 | 33 | Till discharge | 66(36-79) | 64(27-88) | 27/16 | 22/11 | 33 | 10 | 26 | 7 | 23 | 20 | 26 | 7 |